BridgeMD
DIMREATOX study - Reduction in digestive absorption of toxic substances by combined digestive decontamination in intensive care - randomized single-center study
EU CTIS ID: 2024-518739-12-00
What this study is testing
To show the greatest reduction in the plasma concentration of the toxicant(s) (ingested parent molecules) at H24 of randomisation in the intervention group receiving activated charcoal + intestinal purge compared with the control group.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient aged ≥18, intoxicated and hospitalised in intensive care
- Main drug toxicant of functional type (any psychotropic or cardiotropic), adsorbable by activated charcoal
- Main toxicant identified by the history taken by a healthcare professional on the ward or during care prior to the ward
- Main toxicant identified within 3 hours of admission if the patient is already intubated on admission, or within 3 hours of intubation if the patient is intubated on the ward
- Patient intubated for effects attributed to the toxic agent (neuro-respiratory or haemodynamic failure)
- Patient with nasogastric tube or planned nasogastric tube and no contraindications
You likely can't join if
- - No social security affiliation
- - Patients under legal protection
- - Patients deprived of their liberty
- - Non-intubated patient
- Contraindication to the administration of one of the study products (e.g. suspected digestive perforation, intestinal obstruction, inflammatory bowel disease, etc.)
- - Inability to insert a nasogastric tube
See the full eligibility criteria
- Patient aged ≥18, intoxicated and hospitalised in intensive care
- Main drug toxicant of functional type (any psychotropic or cardiotropic), adsorbable by activated charcoal
- Main toxicant identified by the history taken by a healthcare professional on the ward or during care prior to the ward
- Main toxicant identified within 3 hours of admission if the patient is already intubated on admission, or within 3 hours of intubation if the patient is intubated on the ward
- Patient intubated for effects attributed to the toxic agent (neuro-respiratory or haemodynamic failure)
- Patient with nasogastric tube or planned nasogastric tube and no contraindications
- Main toxicant whose assay can be performed by the toxicology laboratory at Lariboisière Hospital AND Inclusion according to the emergency clause
- Written informed consent from a parent/relative/trusted person. In the absence of a parent/relative/trusted person, the patient may be included under the emergency procedure and consent will be obtained as soon as possible.
- - No social security affiliation
- - Patients under legal protection
- - Patients deprived of their liberty
- - Non-intubated patient
- Contraindication to the administration of one of the study products (e.g. suspected digestive perforation, intestinal obstruction, inflammatory bowel disease, etc.)
- - Inability to insert a nasogastric tube
- Repeated vomiting prior to inclusion, making digestive decontamination impossible
- - Digestive haemorrhage in progress or during the previous month
- Ingestion of metals (e.g. iron, caesium, thallium, lead, copper, cadmium)
- - Isolated or predominant alcohol poisoning (e.g. ethyl alcohol, ethylene glycol, methanol)
- - Intoxication by gas (e.g. carbon monoxide or fire fumes)
- Intoxication by a caustic product (acids or bases)
- - Main toxicant ingested under liquid form
- Intoxication by a toxic lesion
- Intoxication by a non-medicated product (e.g. party drugs)
- Intubation for causes not attributed to the ingested toxic substance (e.g. massive inhalation pneumonia)
- - In-body carrier of drug pellets
- - Pregnant or breast-feeding patients
- - Patients being treated for dementia
- - Patient under guardianship or curatorship
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.